RNRikke Linnemann Nielsen

Rikke Linnemann Nielsen

*This is an algorithmically generated author record based on publicly available information.

Rikke Linnemann Nielsen has a total of 149 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Data-driven identification of predictive risk biomarkers for subgroups of osteoarthritis using interpretable machine learning

    by Rikke Linnemann Nielsen, Thomas Monfeuga, Robert R. Kitchen, Line Egerod, Luis G. Leal, August Thomas Hjortshøj Schreyer, Frederik Steensgaard Gade, Carol Sun, Marianne Helenius, Lotte Simonsen, et al.

    Osteoarthritis (OA) is increasing in prevalence and has a severe impact on patients’ lives. However, our understanding of biomarkers driving OA risk remains limited. We developed a model predicting the five-year risk of OA diagnosis, integrating retrospective clinical, lifestyle and biomarker data from the UK Biobank (19,120 patients with OA, ROC-AUC: 0.72, 95%CI (0.71–0.73)). Higher age, BMI and prescription of non-steroidal anti-inflammatory drugs contributed most to increased OA risk prediction ahead of diagnosis. We identified 14 subgroups of OA risk profiles. These subgroups were validated in an independent set of patients evaluating the 11-year OA risk, with 88% of patients being uniquely assigned to one of the 14 subgroups. Individual OA risk profiles were characterised by personalised biomarkers. Omics integration demonstrated the predictive importance of key OA genes and pathways (e.g., GDF5 and TGF-β signalling) and OA-specific biomarkers (e.g., CRTAC1 and COL9A1). In summary, this work identifies opportunities for personalised OA prevention and insights into its underlying pathogenesis.


  • Open Access

    Data-driven identification of predictive risk biomarkers for subgroups of osteoarthritis using an interpretable machine learning framework: a UK biobank study

    by Ramneek Gupta, Rikke Linnemann Nielsen, Thomas Monfeuga, Robert Kitchen, Line Egerod, Luis Leal, August Schreyer, Carol Sun, Marianne Helenius, Lotte Simonsen, et al.

    Osteoarthritis (OA) is increasing in prevalence and has a severe impact on patients’ lives. However, our understanding of biomarkers driving OA risk remains limited. We developed a model predicting the five-year risk of OA, integrating clinical, lifestyle and biomarker data from the UK Biobank (19,120 patients with OA, ROC-AUC:0.72 95%CI (0.71 – 0.73)). Higher age, BMI, and prescription of non-steroidal anti-inflammatory drugs contributed most to increased OA risk prediction. 14 sub-groups of OA risk profiles were identified, and validated in an independent set of patients evaluating the 11-year OA risk, with 88% of patients uniquely assigned to one of the sub-groups. Individual OA risk profiles were characterised by personalised biomarkers. Omics integration demonstrated the predictive importance of key OA genes and pathways (e.g. GDF5 and TGF-β signalling) and identified OA-specific biomarkers (e.g. CRTAC1 and COL9A1). In summary, this work identified opportunities for personalised OA prevention and insights into its underlying pathogenesis.


  • Open Access

    Characteristics of white blood cell count in acute lymphoblastic leukemia: A COST LEGEND phenotype–genotype study

    by Marianne Helenius, Goda Vaitkeviciene, Jonas Abrahamsson, Ólafur Gisli Jonsson, Bendik Lund, Arja Harila‐Saari, Kim Vettenranta, Sirje Mikkel, Martin Stanulla, Elixabet Lopez‐Lopez, et al.

    Background: White blood cell count (WBC) as a measure of extramedullary leukemic cell survival is a well‐known prognostic factor in acute lymphoblastic leukemia (ALL), but its biology, including impact of host genome variants, is poorly understood.Methods: We included patients treated with the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL‐2008 protocol (N = 2347, 72% were genotyped by Illumina Omni2.5exome‐8‐Bead chip) aged 1–45 years, diagnosed with B‐cell precursor (BCP‐) or T‐cell ALL (T‐ALL) to investigate the variation in WBC. Spline functions of WBC were fitted correcting for association with age across ALL subgroups of immunophenotypes and karyotypes. The residuals between spline WBC and actual WBC were used to identify WBC‐associated germline genetic variants in a genome‐wide association study (GWAS) while adjusting for age and ALL subtype associations.Results: We observed an overall inverse correlation between age and WBC, which was stronger for the selected patient subgroups of immunophenotype and karyotypes (ρBCP‐ALL = −.17, ρT‐ALL = −.19; p < 3 × 10−4). Spline functions fitted to age, immunophenotype, and karyotype explained WBC variation better than age alone (ρ = .43, p << 2 × 10−6). However, when the spline‐adjusted WBC residuals were used as phenotype, no GWAS significant associations were found. Based on available annotation, the top 50 genetic variants suggested effects on signal transduction, translation initiation, cell development, and proliferation.Conclusion: These results indicate that host genome variants do not strongly influence WBC across ALL subsets, and future studies of why some patients are more prone to hyperleukocytosis should be performed within specific ALL subsets that apply more complex analyses to capture potential germline variant interactions and impact on WBC.


  • Endothelial dysfunction and thromboembolism in children, adolescents, and young adults with acute lymphoblastic leukemia

    by Liv Andrés-Jensen, Kathrine Grell, Cecilie Utke Rank, Birgitte Klug Albertsen, Ruta Tuckuviene, Rikke Linnemann Nielsen, Line Stensig Lynggaard, Kirsten Brunsvig Jarvis, Petter Quist-Paulsen, Sonata Saulyte Trakymiene, et al.

    Endothelial dysfunction has not previously been investigated as a thrombogenic risk factor among patients with acute lymphoblastic leukemia (ALL), known to be at high risk of thromboembolism. We retrospectively explored the association between three circulating biomarkers of endothelial dysfunction (thrombomodulin, syndecan-1, VEGFR-1) measured in prospectively collected blood samples and risk of thromboembolism in 55 cases and 165 time-matched controls, treated according to the NOPHO ALL2008 protocol. In age-, sex-, and risk group-adjusted analysis, increasing levels of thrombomodulin and VEGFR-1 were independently associated with increased odds of developing thromboembolism (OR 1.37 per 1 ng/mL [95% CI 1.20‒1.56, P < 0.0001] and OR 1.21 per 100 pg/mL [95% CI 1.02‒1.21, P = 0.005], respectively). These associations remained significant when including only samples drawn >30 days before thromboembolic diagnosis. Thrombomodulin levels were on average 3.2 ng/mL (95% CI 2.6–8.2 ng/mL) higher in samples with measurable asparaginase activity (P < 0.0001). Among single nucleotide variants located in or neighboring coding genes for the three biomarkers, none were significantly associated with odds of thromboembolism. If results are validated in another cohort, thrombomodulin and VEGFR-1 could serve as predictive biomarkers, identifying patients in need of preemptive antithrombotic prophylaxis.


  • Open Access

    Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia

    by Morten Tulstrup, Takaya Moriyama, Chuang Jiang, Marie Grosjean, Jacob Nersting, Jonas Abrahamsson, Kathrine Grell, Lisa Lyngsie Hjalgrim, Ólafur Gísli Jónsson, Jukka Kanerva, et al.

    Methotrexate (MTX) during maintenance therapy is essential for curing acute lymphoblastic leukemia (ALL), but dosing strategies aiming at adequate treatment intensity are challenged by interindividual differences in drug disposition. To evaluate genetic factors associated with MTX metabolism, we performed a genome-wide association study in 447 ALL cases from the Nordic Society for Pediatric Haematology and Oncology ALL2008 study, validating results in an independent set of 196 patients. The intergenic single-nucleotide polymorphism rs1382539, located in a regulatory element of DHFR, was associated with increased levels of short-chain MTX polyglutamates (P = 1.1 × 10−8) related to suppression of enhancer activity, whereas rs35789560 in FPGS (p.R466C, P = 5.6 × 10−9) was associated with decreased levels of long-chain MTX polyglutamates through reduced catalytic activity. Furthermore, the FPGS variant was linked with increased relapse risk (P = .044). These findings show a genetic basis for interpatient variability in MTX response and could be used to improve future dosing algorithms.


  • Open Access

    Prediction of Nephrotoxicity Associated With Cisplatin-Based Chemotherapy in Testicular Cancer Patients

    by Sara L Garcia, Jakob Lauritsen, Zeyu Zhang, Mikkel Bandak, Marlene D Dalgaard, Rikke L Nielsen, Gedske Daugaard, Ramneek Gupta

    Cisplatin-based chemotherapy may induce nephrotoxicity. This study presents a random forest predictive model that identifies testicular cancer patients at risk of nephrotoxicity before treatment. Clinical data and DNA from saliva samples were collected for 433 patients. These were genotyped on Illumina HumanOmniExpressExome-8 v1.2 (964 193 markers). Clinical and genomics-based random forest models generated a risk score for each individual to develop nephrotoxicity defined as a 20% drop in isotopic glomerular filtration rate during chemotherapy. The area under the receiver operating characteristic curve was the primary measure to evaluate models. Sensitivity, specificity, and positive and negative predictive values were used to discuss model clinical utility. Of 433 patients assessed in this study, 26.8% developed nephrotoxicity after bleomycin-etoposide-cisplatin treatment. Genomic markers found to be associated with nephrotoxicity were located at NAT1, NAT2, and the intergenic region of CNTN6 and CNTN4. These, in addition to previously associated markers located at ERCC1, ERCC2, and SLC22A2, were found to improve predictions in a clinical feature–trained random forest model. Using only clinical data for training the model, an area under the receiver operating characteristic curve of 0.635 (95% confidence interval [CI] = 0.629 to 0.640) was obtained. Retraining the classifier by adding genomics markers increased performance to 0.731 (95% CI = 0.726 to 0.736) and 0.692 (95% CI = 0.688 to 0.696) on the holdout set. A clinical and genomics-based machine learning algorithm improved the ability to identify patients at risk of nephrotoxicity compared with using clinical variables alone. Novel genetics associations with cisplatin-induced nephrotoxicity were found for NAT1, NAT2, CNTN6, and CNTN4 that require replication in larger studies before application to clinical practice.


  • Candidate single nucleotide polymorphisms and thromboembolism in acute lymphoblastic leukemia – A NOPHO ALL2008 study

    by Kirsten Brunsvig Jarvis, Marissa LeBlanc, Morten Tulstrup, Rikke Linnemann Nielsen, Birgitte Klug Albertsen, Ramneek Gupta, Pasi Huttunen, Ólafur Gisli Jónsson, Cecilie Utke Rank, Susanna Ranta, et al.


  • Open Access

    PSB 2019 Workshop on Text Mining and Visualization for Precision Medicine

    by Graciela Gonzalez-Hernandez, Zhiyong Lu, Robert Leaman, Davy Weissenbacher, Mary Regina Boland, Yong Chen, Jingcheng Du, Juliane Fluck, Casey S. Greene, John Holmes, et al.


  • Top Cited Papers
    Open Access

    Whole grain-rich diet reduces body weight and systemic low-grade inflammation without inducing major changes of the gut microbiome: a randomised cross-over trial

    by Henrik Munch Roager, Josef K Vogt, Mette Kristensen, Lea Benedicte S Hansen, Sabine Ibrügger, Rasmus B Mærkedahl, Martin Iain Bahl, Mads Vendelbo Lind, Rikke L Nielsen, Hanne Frøkiær, et al.

    Objective To investigate whether a whole grain diet alters the gut microbiome and insulin sensitivity, as well as biomarkers of metabolic health and gut functionality. Design 60 Danish adults at risk of developing metabolic syndrome were included in a randomised cross-over trial with two 8-week dietary intervention periods comprising whole grain diet and refined grain diet, separated by a washout period of ≥6 weeks. The response to the interventions on the gut microbiome composition and insulin sensitivity as well on measures of glucose and lipid metabolism, gut functionality, inflammatory markers, anthropometry and urine metabolomics were assessed. Results 50 participants completed both periods with a whole grain intake of 179±50 g/day and 13±10 g/day in the whole grain and refined grain period, respectively. Compliance was confirmed by a difference in plasma alkylresorcinols (pConclusion Compared with refined grain diet, whole grain diet did not alter insulin sensitivity and gut microbiome but reduced body weight and systemic low-grade inflammation. Trial registration number NCT01731366; Results.


  • Open Access

    The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells

    by Stine Ninel Hansen, Natasja Spring Ehlers, Shida Zhu, Mathilde Borg Houlberg Thomsen, Rikke Linnemann Nielsen, Dongbing Liu, Guangbiao Wang, Yong Hou, Xiuqing Zhang, Xun Xu, et al.

    Resistance to taxane-based therapy in breast cancer patients is a major clinical problem that may be addressed through insight of the genomic alterations leading to taxane resistance in breast cancer cells. In the current study we used whole exome sequencing to discover somatic genomic alterations, evolving across evolutionary stages during the acquisition of docetaxel resistance in breast cancer cell lines. Two human breast cancer in vitro models (MCF-7 and MDA-MB-231) of the step-wise acquisition of docetaxel resistance were developed by exposing cells to 18 gradually increasing concentrations of docetaxel. Whole exome sequencing performed at five successive stages during this process was used to identify single point mutational events, insertions/deletions and copy number alterations associated with the acquisition of docetaxel resistance. Acquired coding variation undergoing positive selection and harboring characteristics likely to be functional were further prioritized using network-based approaches. A number of genomic changes were found to be undergoing evolutionary selection, some of which were likely to be functional. Of the five stages of progression toward resistance, most resistance relevant genomic variation appeared to arise midway towards fully resistant cells corresponding to passage 31 (5 nM docetaxel) for MDA-MB-231 and passage 16 (1.2 nM docetaxel) for MCF-7, and where the cells also exhibited a period of reduced growth rate or arrest, respectively. MCF-7 cell acquired several copy number gains on chromosome 7, including ABC transporter genes, including ABCB1 and ABCB4, as well as DMTF1, CLDN12, CROT, and SRI. For MDA-MB-231 numerous copy number losses on chromosome X involving more than 30 genes was observed. Of these genes, CASK, POLA1, PRDX4, MED14 and PIGA were highly prioritized by the applied network-based gene ranking approach. At higher docetaxel concentration MCF-7 subclones exhibited a copy number loss in E2F4, and the gene encoding this important transcription factor was down-regulated in MCF-7 resistant cells. Our study of the evolution of acquired docetaxel resistance identified several genomic changes that might explain development of docetaxel resistance. Interestingly, the most relevant resistance-associated changes appeared to originate midway through the evolution towards fully resistant cell lines. Our data suggest that no single genomic event sufficiently predicts resistance to docetaxel, but require genomic alterations affecting multiple pathways that in concert establish the final resistance stage.